skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Categories

Entrant companies may be based either in Japan or overseas but must have business operations in Japan. However, there are detailed requirements for each category. If you have any questions, please feel free to contact us.

Please click on the + icon to view the full criteria details for each category. To enter a category, click ‘Enter Now’ on that category and complete the entry form. You may enter more than one category.

This Award is to recognize CROs that provide full or specialist services to their clients and which are based either in Japan or the Asia region (including Australia) but which offer services in Japan.

Judging will consider the quality of services and relationships built with clients. It will pay particular attention to the innovative patient recruitment strategies the CRO has brought to the table.

To qualify, candidates must draw on their achievements in the 2021 calendar year.

To enter this category, please answer the following:

  • What particular capabilities and strengths does the CRO offer?
  • How has the company delivered results that exceed sponsor expectations?
  • What innovations in patient recruitment strategy has the CRO brought to its partner?
  • How has it improved its performance, for example, in its quality of data, timelines and transparency?
  • What steps is the company taking towards streamlining data collection and reporting?

 

Enter Now

 

エントリー


The Best New Drug Award recognizes excellence in pharmaceutical development. In this category, the judges will be looking for the small-molecule, biological or vaccine product approved in Japan during the qualifying period that represents the best therapeutic advance in its area.

All recently launched new active substances are eligible to enter as long as they were first licensed in Japan between 1 January-31 December 2021. (Generic and biosimilar products are not eligible.)

Entrants must have played a role in the development of the nominated product, and all parties to joint ventures should be disclosed in the application.

To enter this category, please answer the following:

  • Brand and generic name, indication, company(ies) involved in its development (if more than one company, please detail the relationship between the parties).
  • Date and market of approval and launch
  • Mechanism of action. How does this represent a step forward?
  • Outline evidence for clinical activity. How does this translate into a meaningful therapeutic benefit for patients and over other drugs?
  • What is the potential market size of the candidate?

 

Enter Now

 

エントリー


This award honors outstanding achievements by biotech companies over the qualifying 12-month period of calendar 2021. This could be in terms of moving the business from an early stage to a more mature company, signing a transformative deal, taking its first or a major new product towards the market, or raising significant new funds.

To enter this category, please provide the following information:

 

  • The company’s most significant achievement during the year.
  • Accomplishments in terms of: bringing new products closer to market; raising funds; significant licensing or partnership deals; management not afraid of making hard decisions; using proprietary science or technologies for unmet medical needs; transition from early stage to more mature company.

Enter Now

 

エントリー


Designed to acknowledge excellence in leadership, the winner of this award will be the executive who has exhibited exemplary leadership throughout the 12-month period of calendar 2021. Also important to the judges will be the executive’s career achievements, influence within the industry and leadership qualities.

Entrants must hold a C-suite executive position and be employed by the company at the time of nomination. To enter this category, please answer the following:

  • Name, company and position of the entrant, and the date of taking up this post.
  • Entrant’s greatest achievements during the qualifying year? What has been the direct consequence on company performance?
  • How have these achievements strengthened the candidate’s influence within the industry?
  • Entrant’s greatest strengths as a leader? How did these have a bearing on their achievements this year?
  • What specific previous accomplishments helped with this success? For example, previous scientific or management experience.

 

Enter Now

 

エントリー


Deals considered here are those that involve the licensing of a particular drug, project or group of drugs/projects from one company to another for further development and/ or marketing. (It does not include more involved partnerships between companies to explore particular therapeutic strategies.)

The judges will look at all aspects from monetary and strategic value to the benefits they give to both sides. To qualify, licensing deals must have been closed during calendar year 2021.

To enter this category, please answer the following:

  • Outline the structure of the deal, giving the names of the parties involved, the drug candidate(s) concerned, and what rights it covers.
  • Monetary value of the deal in up-front and milestone payments.
  • Geographic spread of the deal and does it allow any party to enter new markets?
  • Strategic value of the licensed product to the licensee’s business.
  • Please explain how the licensed product was the best possible candidate to complement the rest of the licensee’s pipeline or particular disease franchise.

 

Enter Now

 

エントリー


The Pharma Company of the Year Award honors outstanding achievement by pharmaceutical companies over the qualifying calendar 2021 12-month period. This special award is chosen by Informa's senior editorial team, based on a variety of key metrics as below:

  • Financial performance compared with the same period in previous fiscal year.
  • Strategic advances, looking at most significant achievements over the year.
  • Progress in emerging markets.
  • New product launches including line-extensions and formulations.
  • Advances in the drug pipeline, including major clinical trial reports.

 

You can nominate your company but there is no shortlist and the winner is decided by the informa senior editorial team

 

Enter Now

 

エントリー


The winner of this Award will be an exceptional individual with a consistent history of service, above and beyond the call of duty, throughout their distinguished career in the biotech or pharmaceutical arena, primarily within industry.

We welcome nominees for consideration for this Award but the decision lies with Informa's senior editorial team. The winner may be retired or semi-retired but will still be active in the industry in some capacity.

Any nomination should outline in no more than 1,500 words what the nominee has accomplished during his or her career and say why they are worthy of this Award.

All nominations must include:

  • The name of the nominee.
  • The job title of the nominee (if applicable).
  • The company name (if applicable).
  • Your contact details.
  • The contact details of the nominee.

 

You can nominate your company but there is no shortlist and the winner is decided by the informa senior editorial team

 

Enter Now

 

エントリー